Here are the 10-K annual reports from Relmada Therapeutics, Inc. (RLMD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RLMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLMD filings page.
Relmada Therapeutics, Inc. filed its annual report detailing a major strategic pivot away from esmethadone and psilocybin programs toward two new lead assets, NDV-01 for non–muscle-invasive bladder cancer and sepranolone for Prader–Willi syndrome and related disorders.
The company in-licensed NDV-01 and acquired sepranolone in early 2025, and reported encouraging Phase 2 NDV-01 data with high complete response rates in high‑grade and BCG‑unresponsive NMIBC. Relmada remains a clinical‑stage company with no approved products, recording a $57.4 million net loss in 2025 versus $80.0 million in 2024, and an accumulated deficit of about $698.3 million.
As of December 31, 2025, cash, cash equivalents and short‑term investments were approximately $93.0 million, and as of March 16, 2026 there were 104,890,223 common shares outstanding. The filing emphasizes significant clinical, regulatory, funding and execution risks around the new pipeline‑focused strategy.